Henry Schein (HSIC) Q1 2026 earnings review
Strong Top-Line Rebound Accompanied by Disappointing Cash Flow and GAAP Profits
Henry Schein started 2026 with a solid 6.3% revenue growth to $3.37 billion, showing an accelerating recovery from the late-2023 cyber incident. The top line was driven by a robust performance in Global Dental Distribution, where merchandise and equipment sales grew ~9%. Non-GAAP EPS surged 14.8% to $1.32. However, the quality of these earnings is questionable: GAAP Net Income actually fell 2.3% due to ballooning SG&A and restructuring costs, and Operating Cash Flow reversed dramatically from a positive $37 million a year ago to a negative $97 million. Despite these underlying structural concerns, new CEO Fred Lowery reaffirmed FY26 guidance and remains committed to a $125 million run-rate operating income improvement by year-end.
🐂 Bull Case
The core Dental Distribution segment is accelerating rapidly. Global Dental Merchandise grew 9.0% and Global Equipment grew 8.6%, proving that the company has fully won back customer confidence and market share following the prior cyber disruptions.
Global Value-Added Services (+10.6%) and Global Specialty Products (+8.1%) are growing faster than the base distribution business, successfully driving the long-term BOLD+1 strategy to shift the profit mix toward higher-margin revenues.
🐻 Bear Case
While Non-GAAP EPS rose 14.8%, GAAP Net Income declined 2.3%. SG&A expenses spiked by 9.6% (outpacing the 6.3% revenue growth), relying on $46 million of add-backs to make the bottom line look attractive.
Global Medical Distribution sales decelerated to a meager 1.7% growth rate (1.3% internal). This heavily contrasts with the robust dental performance and suggests underlying weakness in physician office traffic or product demand.
⚖️ Verdict: ⚪
Neutral. The top-line sales momentum in the core dental business is undeniably strong, but the severe cash burn and reliance on non-GAAP adjustments to show profit growth leave significant execution risk for the rest of the year.
Key Themes
Global Dental Distribution Rebound Accelerating
The core dental distribution machine is running hot. Global Dental Merchandise sales grew 9.0% and Equipment sales grew 8.6% YoY. This marks a massive, accelerating turnaround compared to a year ago when Q1 2025 equipment sales were flat or declining. The U.S. performance is particularly strong, confirming the success of customer win-back initiatives following the 2023 cyberattack.
Leadership Change and Value Creation Execution
New CEO Fred Lowery has officially taken the helm, emphasizing a commitment to the ongoing value-creation initiatives. The company is targeting an annual operating income improvement of greater than $200 million, with a $125 million run-rate expected by the end of 2026. This focus on centralized procurement, automation, and growing corporate brands drove a slight gross margin expansion to 31.77% in Q1.
Technology and Cloud Adoption Upward Trajectory
Global Technology sales maintained a stable, robust growth rate of 7.0%. The continuous transition of dental practices to cloud-based solutions (like Dentrix Ascend and Dentally) and the integration of new generative AI tools through the Amazon Web Services partnership are solidifying recurring revenue streams.
Medical Segment Severely Lagging
The Global Medical Distribution segment is decelerating. It posted a meager 1.7% YoY growth (1.3% internal) in Q1 2026, dragging down the overall company average. If this weakness stems from lower respiratory testing demand or pricing pressures, it could act as a permanent anchor on total revenue growth throughout FY26.
SG&A Bloat Contradicts Margin Expansion Narrative
Despite management touting value-creation and efficiency plans, Q1 data shows a reversing trend in core operating leverage. Selling, General, and Administrative (SG&A) expenses surged by 9.6% ($809M vs $738M), vastly outpacing the 6.3% revenue growth. This expense bloat directly caused the 2.3% drop in GAAP Net Income, contradicting the narrative of structural margin improvement unless heavy non-GAAP adjustments are applied.
Operating Cash Flow Collapses
A major red flag: Net cash from operating activities reversed from a positive $37 million in 25Q1 to a negative $97 million in 26Q1. This cash burn was driven by a massive $223 million outflow related to accounts payable and accrued expenses, alongside an inventory build. Moving opposite to Net Income, this signals potential working capital management issues or the aggressive unwinding of prior quarter payables.
Other KPIs
Accelerating from $259 million (+11.6% YoY). This metric paints a much healthier picture of operations than GAAP Net Income, reflecting the core profitability of the business before $12 million in restructuring costs and $27 million in acquisition-related amortization are subtracted.
Stable capital return execution. The company bought back 1.6 million shares at an average price of $77.64. The pace is slightly lower than the $161 million repurchased in Q1 of the prior year, leaving $655 million authorized for future buybacks.
Increasing leverage. Total debt (Bank credit lines + current maturities + long-term debt) rose to $3.40B from $3.10B at the end of FY25. This $300 million sequential increase in debt funded the negative operating cash flow, M&A activity, and share repurchases during the quarter.
Guidance
Decelerating expectation. The company reaffirmed this guidance range. Given that Q1 just delivered 6.3% growth, maintaining the 3-5% target implies management expects revenue growth to cool down significantly in the remaining three quarters of the year.
Stable. Unchanged from prior guidance. The midpoint ($5.30) implies approximately 6.6% growth over FY25's $4.97. With Q1 already delivering 14.8% Non-GAAP EPS growth, this full-year target appears conservative and leaves room for upward revisions if the restructuring savings flow through as planned.
Decelerating. Guidance remains unchanged. After posting an 11.6% Adjusted EBITDA increase in Q1, a full-year target of mid-single digits suggests expected margin pressure or heavier investments in the back half of the year.
Key Questions
Path to GAAP Profitability
SG&A grew nearly 10% in Q1, driving a decline in GAAP Net Income despite strong revenue growth. When will the $125M run-rate value creation savings actually flow through to unadjusted, GAAP operating leverage?
Working Capital and Cash Flow
Operating Cash Flow saw a massive negative swing to -$97M due to payables and accrued expense outflows. Was this a one-time unwind of deferred payments, or a structural change in working capital dynamics?
Medical Segment Recovery
With Global Medical Distribution growing a meager 1.7%, what specific catalysts or new product lines are needed to re-accelerate this segment to match the growth seen in the dental business?